Key statistics dashboard for Lixte Biotechnology Holdings, Inc. (LIXT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Lixte Biotechnology Holdings, Inc. is a drug discovery company focused on developing new treatments. It employs biomarker technology to identify crucial enzyme targets associated with serious, widespread diseases, then designs innovative compounds to act upon these targets.
Stock Data
| Price | $7.21 |
| Market Cap | $89M |
| Enterprise Value | $77.5M |
| Beta | 0.95 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -7.21 |
| Price / Book | 4.06 |
| P/S | 0.00 |
| EV/EBITDA | -8.71 |
| EV/Sales | 0.00 |
| EV/FCF | -14.21 |
| P/FCF | -16.33 |
| Earnings Yield | -8.94% |
| FCF Yield | -6.12% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -74.82% |
| Return on Assets | -32.59% |
| Return on Invested Capital | -30.52% |
| Return on Capital Employed | -31.66% |
Financial Health
| Current Ratio | 12.87 |
| Quick Ratio | 12.87 |
| Cash Ratio | 8.45 |
| Debt / Equity | 0.05 |
| Debt / Assets | 4.13% |
| Net Debt / EBITDA | 1.30 |
| Interest Coverage | -1233.08 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.85 |
| Cash per share | 0.94 |
| FCF per share | -0.41 |
| Tangible Book Value per share | 1.85 |
| Dividend per share | 0.00 |
Related companies: ALLR · BCTX · CASI · CING · CLSD · ENTO · HOTH
Explore sector: Healthcare · Biotechnology
More sections of LIXT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks